TB-500 5mg

1. 1

   Remove the 5 mg lyophilized TB-500 vial from −20 °C storage and allow it to equilibrate to room temperature for approximately 15 minutes.

2. 2

   Swab the rubber stopper of both the peptide vial and the bacteriostatic water vial with a sterile alcohol swab and allow them to air-dry completely.

3. 3

   Using a sterile syringe, precisely draw 2.0 mL of bacteriostatic water.

4. 4

   Insert the syringe needle at an angle into the peptide vial and slowly inject the bacteriostatic water down the inner glass wall to prevent shearing the peptide.

5. 5

   Gently roll or swirl the vial until the lyophilized cake is fully dissolved into a clear solution without shaking vigorously.

6. 6

   Label the vial with the reconstitution date, final concentration (2.5 mg/mL), and immediately place it into refrigerated storage between 2–8 °C.

Overview

TB-500 is a synthetic peptide derived from the active actin-binding domain of the naturally occurring 43-amino-acid peptide thymosin beta-4. Structurally, it commonly corresponds to the short peptide motif Ac-LKKTETQ, which represents residues 17 through 23 of the parent protein. This specific domain is identified as the minimal sequence required to sequester monomeric globular actin, a biological function central to dynamic cellular cytoskeleton remodeling and cell mobility. In preclinical research models, TB-500 is evaluated for its downstream actions in cell migration, microvascular tube formation, and extracellular matrix remodeling. By modulating free actin dynamics, it promotes the directional movement of keratinocytes, fibroblasts, and endothelial cells toward target sites of injury. Investigations also examine its secondary signaling roles in downregulating focal inflammatory responses and upregulating local vascular endothelial factors in soft tissues. While full-length thymosin beta-4 has entered clinical development across multiple tissue injury indications, TB-500 remains strictly a preclinical research compound. It is frequently applied in animal models and cell culture frameworks assessing tendon repair, dermal wound healing, and musculoskeletal rehabilitation to elucidate fragment-specific bioactivity and therapeutic potential.

1. 1.Philp et al., The FASEB Journal, 2003 — Identification of the central actin-binding sequence LKKTETQ as essential for angiogenic and migratory properties of thymosin beta-4
2. 2.Goldstein et al., Expert Opinion on Biological Therapy, 2012 — Structure, multi-functional cellular biology, and clinical evaluation of thymosin beta-4 in wound and tissue repair
3. 3.McGuire et al., Applied Sciences, 2026 — Scoping review on thymosin beta-4 and TB-500 literature across musculoskeletal repair, wound healing, and regeneration models
4. 4.Xue et al., Structure, 2014 — Structural basis and mechanisms of actin-monomer sequestration by beta-thymosins

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.